Vemurafenib

Excerpt

A 38-year-old woman had metastatic melanoma, and elected to crush and chew vemurafenib [dosage not stated] due to her severe phobia of swallowing tablets. Her main reported side effect was a keratosis pilaris rash on her forehead and shoulder areas [duration of treatment to reaction onset not stated]. Six weeks after starting therapy, she was admitted with severe nausea and vomiting. Vemurafenib was withheld for 10 days. With improvement of nausea, vemurafenib was restarted. Four weeks later, she was re-admitted with progressive disease and brain metastases; she died 1 week later [outcome of rash and cause of death not stated]. …